POLLEN GRAINS AS TROJAN HORSES FOR ORAL VACCINATION

花粉粒作为口服疫苗的特洛伊木马

基本信息

  • 批准号:
    8356940
  • 负责人:
  • 金额:
    $ 220.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-09-30 至 2017-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (Provided by the applicant) Abstract: We propose to transform pollen grains into a powerful and broadly applicable oral vaccination platform. Oral vaccine delivery has been a longstanding goal in the field of vaccination because it is needle-free, can be selfadministered and can produce both systemic and mucosal immune responses. Mucosal immunity is a powerful host-regulated defense at the mucosal surfaces that can neutralize pathogens while they are still outside the human body, before they can cause infection. The gastrointestinal mucosa like other mucosal surfaces suffers from constant onslaughts of microbes and forms a major portal of pathogen entry. Therefore, being able to stimulate mucosal immunity at the gastrointestinal mucosa will offer a tremendous immunological advantage to humans to help fight-off microbial invasions. The major roadblocks that continue to obstruct successful oral vaccination are the degradation of vaccines in the stomach and their poor uptake across the intestinal epithelial cell lining. Pollen grains are a natural engineering marvel with potential to address these roadblocks. Pollen grains have very tough exterior shells, which can withstand the acidic and enzymatic environment of the stomach and they can pass in to the body as intact particles across the tight epithelial cells of the gastrointestinal mucosa. We propose to exploit these fantastic natural particles and transform them into ¿Trojan horses¿ to safely ferry vaccine antigens across the harsh environment of the stomach and across the tight epithelial barrier, into the body. We have tested the feasibility of our seemingly peculiar idea by feeding mice with pollen grains filled with ovalbumin as a model antigen. Anti-ovalbumin immunoglobulin G (IgG) antibodies were produced in mouse serum after the vaccination. Importantly, the anti-ovalbumin IgG levels induced by pollen grains were found to be more than ten-fold higher than the anti-ovalbumin IgG levels induced by the use of cholera toxin (CT) as a positive control. This result is very significant because CT as a mucosal adjuvant is the current gold standard for oral vaccination and our data suggests that pollen grains are superior to CT. We are very excited by this discovery and we propose to further develop this promising strategy for oral vaccination through a multidisciplinary approach bridging the fundamentals of bioengineering, drug delivery and vaccinology. Our two complementary goals that will move this approach closer to human trials are: (i) characterize pollen grains and develop a mechanistic understanding of their Trojan ability, and (ii) understand mucosal and systemic immune responses generated by pollen grain-based oral vaccination and explore the potential of immunomodulation by the synergistic use of adjuvants. Overall, this pollen grain-based oral vaccine delivery platform is expected to be highly versatile and thus has potential to be harnessed for development of mucosal vaccines against a host of infectious diseases. Public Health Relevance: This project seeks to develop a novel methodology for oral vaccination, which is painless, child-friendly, safer and functionally superior to the exiting intramuscular route of vaccination using hypodermic needles. The delivery methodology will have broad applicability and will be able to deliver a broad range of vaccines.
描述(由申请人提供) 摘要:我们建议将花粉颗粒转化为一个功能强大、适用范围广的口服疫苗接种平台。口服疫苗接种一直是疫苗接种领域的一个长期目标,因为它是无针的,可以自我给药,可以产生全身和粘膜免疫反应。粘膜免疫是一种强大的宿主调节的粘膜表面防御,可以在病原体仍在人体外时中和它们,以免它们引起感染。胃肠粘膜像其他粘膜表面一样,不断遭受微生物的侵袭,形成病原体进入的主要门户。因此,能够在胃肠道粘膜激发粘膜免疫将为人类提供巨大的免疫优势,帮助抵御微生物的入侵。继续阻碍成功口服疫苗接种的主要障碍是疫苗在胃内的降解以及它们在肠道上皮细胞层中的低摄取率。花粉 谷物是一种天然的工程奇迹,有可能解决这些障碍。花粉颗粒有非常坚硬的外壳,可以承受胃的酸性和酶环境,它们可以作为完整的颗粒穿过胃肠道粘膜的紧密上皮细胞进入体内。我们建议利用这些奇妙的天然颗粒并将它们转化为特洛伊木马,以安全地将疫苗抗原运送到胃的恶劣环境中,穿过紧密的上皮屏障进入体内。我们用填充了卵清蛋白的花粉颗粒作为模型抗原,测试了我们这个看似奇怪的想法的可行性。免疫后小鼠血清中产生抗卵清蛋白免疫球蛋白G(Ig G)抗体。重要的是,花粉诱导的抗卵清蛋白免疫球蛋白水平比用霍乱毒素(CT)作为阳性对照诱导的抗卵清蛋白免疫球蛋白水平高10倍以上。这一结果非常有意义,因为CT作为一种粘膜佐剂是目前口服疫苗的黄金标准,我们的数据表明,花粉粒优于CT。我们对这一发现感到非常兴奋,我们建议通过一种多学科的方法进一步发展这一前景看好的口服疫苗接种战略,将生物工程、药物输送和疫苗学的基本原理联系起来。我们的两个相辅相成的目标将使这一方法更接近人体试验:(I)描述花粉颗粒的特征并发展对其特洛伊木马的机械理解 了解基于花粉颗粒的口服疫苗产生的粘膜和系统免疫反应,并探索通过协同使用佐剂进行免疫调节的潜力。总体而言,这种基于花粉颗粒的口服疫苗递送平台预计将具有高度的通用性,因此有可能被用于开发针对一系列传染病的粘膜疫苗。 公共卫生相关性:该项目寻求开发一种新的口服疫苗接种方法,该方法无痛、对儿童友好、更安全,并且在功能上优于现有的使用皮下注射针的肌肉内接种路线。提供方法将具有广泛的适用性,并将能够提供广泛的疫苗。

项目成果

期刊论文数量(8)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(3)
Demystifying particle-based oral vaccines.
  • DOI:
    10.1080/17425247.2021.1946511
  • 发表时间:
    2021-10
  • 期刊:
  • 影响因子:
    6.6
  • 作者:
    Gonzalez-Cruz P;Gill HS
  • 通讯作者:
    Gill HS
Pollen grains as a novel microcarrier for oral delivery of proteins.
Pollen grains for oral vaccination.
Ragweed pollen as an oral vaccine delivery system: Mechanistic insights.
From allergen to oral vaccine carrier: A new face of ragweed pollen.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Harvinder Singh Gill其他文献

ASO Visual Abstract: Tumor-Infiltrating Lymphocytes (TILs) as a Biomarker of Abscopal Effect of Cryoablation in Breast Cancer—A Pilot Study
  • DOI:
    10.1245/s10434-021-11240-2
  • 发表时间:
    2022-01-25
  • 期刊:
  • 影响因子:
    3.500
  • 作者:
    Sonia Y. Khan;Michael W. Melkus;Fahmida Rasha;Maribel Castro;Victoria Chu;Luis Brandi;Hafiz Khan;Harvinder Singh Gill;Kevin Pruitt;Rakhshanda Layeequr Rahman
  • 通讯作者:
    Rakhshanda Layeequr Rahman

Harvinder Singh Gill的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Harvinder Singh Gill', 18)}}的其他基金

Development of a Universal Influenza Vaccine Against Influenza A and B Viruses
开发针对甲型和乙型流感病毒的通用流感疫苗
  • 批准号:
    10053298
  • 财政年份:
    2018
  • 资助金额:
    $ 220.5万
  • 项目类别:
Microneedles for treatment of peanut allergy
微针治疗花生过敏
  • 批准号:
    9662551
  • 财政年份:
    2018
  • 资助金额:
    $ 220.5万
  • 项目类别:
Development of a Universal Influenza Vaccine Against Influenza A and B Viruses
开发针对甲型和乙型流感病毒的通用流感疫苗
  • 批准号:
    10291415
  • 财政年份:
    2018
  • 资助金额:
    $ 220.5万
  • 项目类别:
Microneedles for treatment of peanut allergy
微针治疗花生过敏
  • 批准号:
    10219057
  • 财政年份:
    2018
  • 资助金额:
    $ 220.5万
  • 项目类别:
Development of a Universal Influenza Vaccine Against Influenza A and B Viruses
开发针对甲型和乙型流感病毒的通用流感疫苗
  • 批准号:
    10519103
  • 财政年份:
    2018
  • 资助金额:
    $ 220.5万
  • 项目类别:
Microneedles for treatment of peanut allergy
微针治疗花生过敏
  • 批准号:
    10471226
  • 财政年份:
    2018
  • 资助金额:
    $ 220.5万
  • 项目类别:
Engineering an intranasal universal influenza vaccine
设计鼻内通用流感疫苗
  • 批准号:
    9526306
  • 财政年份:
    2017
  • 资助金额:
    $ 220.5万
  • 项目类别:
Nanoengineered virus-mimics as templates for design of a universal influenza A va
纳米工程病毒模拟物作为通用甲型流感病毒设计的模板
  • 批准号:
    8499243
  • 财政年份:
    2012
  • 资助金额:
    $ 220.5万
  • 项目类别:
Nanoengineered virus-mimics as templates for design of a universal influenza A va
纳米工程病毒模拟物作为通用甲型流感病毒设计的模板
  • 批准号:
    8285558
  • 财政年份:
    2012
  • 资助金额:
    $ 220.5万
  • 项目类别:
Targeting the oral cavity epithelium for inducing mucosal immunity against HIV
靶向口腔上皮诱导针对 HIV 的粘膜免疫
  • 批准号:
    8249376
  • 财政年份:
    2011
  • 资助金额:
    $ 220.5万
  • 项目类别:

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 220.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 220.5万
  • 项目类别:
    Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 220.5万
  • 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 220.5万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 220.5万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 220.5万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 220.5万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 220.5万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 220.5万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 220.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了